Prostate specific membrane antigen
Prostate-specific membrane antigen (PSMA), encoded by the FOLH1 gene, is a type II transmembrane glycoprotein with enzymatic activity as glutamate carboxypeptidase II (GCPII).
Prostate-specific membrane antigen (PSMA), encoded by the FOLH1 gene, is a type II transmembrane glycoprotein with enzymatic activity as glutamate carboxypeptidase II (GCPII). Although named for its prominent expression in prostate tissue, PSMA is not exclusive to the prostate. It is expressed at lower levels in selected normal tissues, including the nervous system, kidney, and small-intestinal epithelium, and is frequently markedly upregulated in prostate cancer, particularly in advanced and metastatic disease.
The extracellular domain of PSMA catalyzes the hydrolysis of glutamate-containing substrates, including folate-related compounds and N-acetylaspartylglutamate. Its membrane localization, disease-associated overexpression, and efficient ligand-induced internalization have made PSMA an important biomarker and therapeutic target. PSMA-binding small molecules, antibodies, antibody–drug conjugates, radioligands, and chimeric antigen receptor (CAR) T cells have consequently been investigated for prostate-cancer imaging and treatment. In targeted radionuclide therapy, PSMA ligands can deliver beta-emitting radionuclides such as lutetium-177 or alpha-emitting radionuclides such as actinium-225 to PSMA-expressing tumor cells. PSMA expression may also support combination strategies directed at the tumor microenvironment, immune-checkpoint blockade, or additional tumor-associated targets such as integrin αvβ3.
PSMA should be distinguished from prostate-specific antigen (PSA). PSA is a secreted serine protease commonly used as a clinical biomarker, whereas PSMA is a cell-surface enzyme and molecular target. PSMA-directed approaches are therefore intended either to visualize PSMA-positive lesions or to exploit the antigen for selective delivery of radiation, immune effector activity, or other cytotoxic mechanisms.
Where the papers sit
12 papers from the last 6 months study prostate specific membrane antigen directly · updated from PubMed 16 Nov 2026
Study type 2 clinical trials · 2 observational · 8 preclinical
Themes 3 themes · 2 new directions
-
PSMA-Targeted Prostate Therapies
PSMA targeting is being combined with cytotoxic nanotherapy, radionuclide delivery, redox control and immune activation in prostate cancer. Glucose oxidase nanotherapy, PGC1α-expressing nanogels and dual PSMA–integrin αvβ3 radioligands seek stronger tumor control while limiting systemic toxicity. A PSMA DNA vaccine is paired with PD-1 blockade to enhance antitumor immunity. Detection platforms such as DNA-walker photothermal biosensors sit alongside these treatments, reflecting a broader push toward multifunctional PSMA-directed care.
5 papers · 41.7%
-
Clinical PSMA PET Imaging
PSMA PET is expanding from prostate cancer lesion detection to biopsy guidance, recurrence assessment and treatment-response prediction. [68Ga]Ga-PSMA-11 PET/CT is being compared with MRI-guided biopsy and used after focal therapy for suspected recurrence. Combining PSMA PET with [18F]FDG PET may improve pretreatment risk stratification in metastatic castration-resistant disease. Early scans are also being tested as predictors of six-month systemic-therapy control, while applications in renal cell carcinoma remain exploratory.
4 papers · 33.3%
-
PSMA Radiotracer Development
PSMA imaging is moving toward higher-contrast radiotracers with less nonspecific retention and more useful pharmacokinetics. Gallium-68 and fluorine-18 AlF-labeled ligands are being optimized through linker and benzyl-substitution changes. The work also extends PSMA-directed radiotheranostics beyond conventional small molecules, including engineered mechanosensitive mesenchymal stromal cells. Whether these platforms improve tumor control as well as PET imaging remains open.
3 papers · 25%
PSMA is used as an inducible synthetic biomarker rather than an endogenous tumor target
Engineered mechanosensitive mesenchymal stem cells in multiple tumor models showed that PSMA expression can be induced locally in response to tumor stiffness, enabling ⁶⁸Ga-PSMA-617 PET detection and ¹⁷⁷Lu-AB-PSMA-617 treatment even when tumors lack endogenous PSMA 42624106Aug. This changes PSMA from a naturally occurring molecular address used for imaging or delivery into a programmable radiotheranostic entry point that can be installed across tumor types.
PSMA is used as a vaccine antigen to generate antitumor immunity
A Nanoplasmid DNA vaccine encoding human PSMA in prophylactic and therapeutic prostate cancer models used PSMA to prime cellular and humoral immunity, prevent metastasis, and enhance PD-1 blockade 42176796May. Rather than serving only as a surface target for externally delivered imaging agents or therapeutics, PSMA becomes the antigen around which an active systemic antitumor immune response is organized.
Papers
The 12 papers from the last 6 months that study prostate specific membrane antigen directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
PSMA-Targeted Prostate Therapies (5)
- A dual signal amplification photothermal biosensor based on Sn-CDs/NPC and DNA walker for prostate cancer cell detection. Mikrochimica acta · 26 Oct 2026 PMID 42931874
- PSMA and Integrin αvβ3 Dual-Targeted Radioligands for Prostate Cancer Targeted Radionuclide Therapy. Journal of medicinal chemistry · 27 Jul 2026 PMID 42503815
- Targeted intracellular glucose oxidase nanotherapy enables single-dose treatment of prostate cancer. International journal of pharmaceutics · 13 Jul 2026 PMID 42442513
- PGC1α expression using targeted redox-responsive nanogels protects against prostate cancer in vivo. Journal of controlled release : official journal of the Controlled Release Society · 29 Jun 2026 PMID 42372825
- Nanoplasmid PSMA DNA vaccine primes antitumor immunity and enhances response to PD-1 blockade against prostate cancer. Cancer letters · 23 May 2026 PMID 42176796
Clinical PSMA PET Imaging (4)
- Can early 68Ga-PSMA-11 PET/CT predict 6-month disease control in patients receiving first-line systemic therapy for metastatic clear-cell renal cell carcinoma? Protocol for the multicentre prospective phase II PSMA-RENAL study in Belgium. BMJ open · 18 Sept 2026 PMID 42760067
- PSMA PET Imaging for Prostate Cancer Recurrence After Minimally Invasive Focal Therapy: A Single-Center Retrospective Study. Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 20 Aug 2026 PMID 42624652
- Prognostic Value of [18F]FDG PET Combined with [68Ga]Ga-PSMA PET as Pretreatment Imaging in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with [177Lu]Lu-PSMA-617. Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 13 Aug 2026 PMID 42595484
- PCa Detection in PI-RADS 4 and 5 Lesions: Comparison of [68Ga]Ga-PSMA-11 PET/CT-Guided Robot-Assisted Biopsy Versus mpMRI Cognitive-Fusion TRUS-Guided Prostate Biopsy. Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 18 Jun 2026 PMID 42315309
PSMA Radiotracer Development (3)
- Acridine-Based [68Ga]Ga- and [18F]AlF-Labeled PSMA Radiotracers Enabling High-Contrast PET Imaging with Minimized Undesired Retention. Journal of medicinal chemistry · 10 Sept 2026 PMID 42720466
- Engineered mechanosensitive MSCs enable synthetic radiotheranostic targeting across tumor types. Cell stem cell · 20 Aug 2026 PMID 42624106
- Structure-property relationships of benzyl-substituted urea-based ligands with Phe-Phe linker targeting prostate-specific membrane antigen labeled with gallium-68. Bioorganic chemistry · 18 Jun 2026 PMID 42314598
By study type
Clinical trials (2)
- Can early 68Ga-PSMA-11 PET/CT predict 6-month disease control in patients receiving first-line systemic therapy for metastatic clear-cell renal cell carcinoma? Protocol for the multicentre prospective phase II PSMA-RENAL study in Belgium. BMJ open · 18 Sept 2026 PMID 42760067
- PCa Detection in PI-RADS 4 and 5 Lesions: Comparison of [68Ga]Ga-PSMA-11 PET/CT-Guided Robot-Assisted Biopsy Versus mpMRI Cognitive-Fusion TRUS-Guided Prostate Biopsy. Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 18 Jun 2026 PMID 42315309
Observational studies and case reports (2)
- PSMA PET Imaging for Prostate Cancer Recurrence After Minimally Invasive Focal Therapy: A Single-Center Retrospective Study. Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 20 Aug 2026 PMID 42624652
- Prognostic Value of [18F]FDG PET Combined with [68Ga]Ga-PSMA PET as Pretreatment Imaging in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with [177Lu]Lu-PSMA-617. Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 13 Aug 2026 PMID 42595484
Preclinical: animal, cell and lab studies (8)
- A dual signal amplification photothermal biosensor based on Sn-CDs/NPC and DNA walker for prostate cancer cell detection. Mikrochimica acta · 26 Oct 2026 PMID 42931874
- Acridine-Based [68Ga]Ga- and [18F]AlF-Labeled PSMA Radiotracers Enabling High-Contrast PET Imaging with Minimized Undesired Retention. Journal of medicinal chemistry · 10 Sept 2026 PMID 42720466
- Engineered mechanosensitive MSCs enable synthetic radiotheranostic targeting across tumor types. Cell stem cell · 20 Aug 2026 PMID 42624106
- PSMA and Integrin αvβ3 Dual-Targeted Radioligands for Prostate Cancer Targeted Radionuclide Therapy. Journal of medicinal chemistry · 27 Jul 2026 PMID 42503815
- Targeted intracellular glucose oxidase nanotherapy enables single-dose treatment of prostate cancer. International journal of pharmaceutics · 13 Jul 2026 PMID 42442513
- PGC1α expression using targeted redox-responsive nanogels protects against prostate cancer in vivo. Journal of controlled release : official journal of the Controlled Release Society · 29 Jun 2026 PMID 42372825
- Structure-property relationships of benzyl-substituted urea-based ligands with Phe-Phe linker targeting prostate-specific membrane antigen labeled with gallium-68. Bioorganic chemistry · 18 Jun 2026 PMID 42314598
- Nanoplasmid PSMA DNA vaccine primes antitumor immunity and enhances response to PD-1 blockade against prostate cancer. Cancer letters · 23 May 2026 PMID 42176796
Written from 12 PubMed abstracts, each one listed by PMID above. Published: 2026-08-20. Last written: 2026-09-20 by GPT. Drafted by language models from published abstracts; not medical advice.